PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

BioInnovation Institute selects Munich and Berlin as locations for European cardiometabolic initiative

Two German innovation hubs will strengthen BioInnovation Institute (BII) and the Novo Nordisk Foundation’s pan-European CardioMetabolic Bridge initiative and accelerate the translation of promising cardiometabolic research into new treatments and biotech companies

BioInnovation Institute (BII), a leading international institute for life science and deep tech innovation, has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative. The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic diseases.

Supported by the Novo Nordisk Foundation, CardioMetabolic Bridge is a pan-European initiative designed to bridge the gap between academic research and commercial drug development. With Munich and Berlin joining London as key locations in the network, BII aims to strengthen access to outstanding scientific research, clinical expertise, entrepreneurial talent and industry networks across Europe.

Germany is home to a strong life science and medical research ecosystem, with world-class universities, hospitals, research institutions and biotech companies. The selection of Munich and Berlin reflects the strength and complementary capabilities of the two innovation environments and their potential to contribute to the next generation of cardiometabolic therapies.

“Germany has outstanding scientific capabilities and some of Europe’s most dynamic life science ecosystems. We see significant opportunities in both Munich and Berlin to connect excellent research with the entrepreneurial expertise, infrastructure and industry networks needed to bring new therapies closer to patients. Establishing our presence in these two locations is an important step in expanding CardioMetabolic Bridge and strengthening Europe’s ability to turn scientific discoveries into meaningful healthcare solutions,” says Jens Nielsen, CEO of BioInnovation Institute.

Connecting outstanding research with the resources to create impact

Despite Europe’s strong position in cardiometabolic research, many promising scientific discoveries never make the transition from academic laboratories into drug development. Early-stage researchers and innovators often lack the funding, infrastructure, industry expertise and commercial support required to advance their discoveries.

CardioMetabolic Bridge seeks to address this challenge by providing selected research projects with early-stage funding, access to laboratory infrastructure, scientific and commercial mentoring, drug discovery and development expertise, and connections to investors and industry partners.

The initiative focuses on research addressing cardiometabolic diseases, including obesity, type 2 diabetes and cardiovascular disease, with the ambition of accelerating the development of next-generation therapeutics and supporting the creation of new biotech companies.

Through its interconnected European hubs, BII will work closely with universities, hospitals, research institutions and other ecosystem partners to identify promising discoveries and support their progression towards validated drug candidates and commercial opportunities.

Building a connected European innovation ecosystem

Munich and Berlin will become important parts of BII’s expanding European network, complementing the London hub at Victoria House in the Knowledge Quarter and BII’s headquarters in Copenhagen.

By establishing a presence in some of Europe’s leading life science environments, BII aims to connect scientific excellence across national borders, facilitate collaboration and provide researchers with access to the expertise and resources needed to translate innovation into meaningful healthcare solutions.

“Our ambition with CardioMetabolic Bridge is to create a European platform where scientific excellence can be translated into real-world impact. By connecting leading research environments in different countries, we can help promising discoveries overcome the barriers that often prevent them from progressing beyond the academic laboratory. Ultimately, this is about accelerating the development of new treatments for people living with cardiometabolic diseases and strengthening Europe’s life science innovation ecosystem,” says Jens Nielsen, CEO of BioInnovation Institute.

About CardioMetabolic Bridge

CardioMetabolic Bridge is a pan-European initiative driven by BioInnovation Institute and supported by the Novo Nordisk Foundation with up to DKK 450 million over six years. The initiative aims to accelerate the translation of promising academic research in cardiometabolic diseases into validated drug discovery projects, new therapeutics and biotech companies. By connecting innovation hubs and research ecosystems across Europe, CardioMetabolic Bridge seeks to strengthen Europe’s capacity to turn scientific discoveries into healthcare solutions.

About BioInnovation Institute

The BioInnovation Institute (BII) is Europe’s leading innovation institute backed by the Novo Nordisk Foundation and many significant industry partners. Its mission is to bring science to life through the successful BII innovation platform, accelerating innovation’s journey to the market. BII supports collaborative, interdisciplinary innovation across Life Sciences and Deep Tech, helping transform cutting-edge research into viable companies so that new discoveries can deliver real impact for people and society.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC